Population Pharmacokinetics of Necitumumab in Cancer Patients

Necitumumab is a second-generation, recombinant, human immunoglobulin G1, epidermal growth factor (EGFR) receptor antibody that specifically blocks the ligand binding site of EGFR. Necitumumab potentially acts by blocking ligand epidermal growth factor (EGF) binding-mediated activation of the EGFR s...

Descripción completa

Detalles Bibliográficos
Autores principales: Long, Amanda, Chigutsa, Emmanuel, Wallin, Johan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5385201/
https://www.ncbi.nlm.nih.gov/pubmed/27696220
http://dx.doi.org/10.1007/s40262-016-0452-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5385201/
https://www.ncbi.nlm.nih.gov/pubmed/27696220
http://dx.doi.org/10.1007/s40262-016-0452-x

Ejemplares similares